Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

Bombay Stock Exchange Of India (BSE)

Bombay Stock Exchange Of India (BSE) Bombay Exchange Sensitive Index ( SENSEX) - the benchmark index of the Bombay Stock Exchange (BSE)  also called the "BSE 30", is a widely used ...…

Assets

Assets Assets is owned by a company or a person. Property are listed on a company's balance sheet and include tangible things like inventory, equipment, and ...…

Money Definition

Money Definition A government issue money in the form of  currency, coins  and  paper. Money in these forms Serves As a Medium For All Financial transactions. ...…

Mean For Preferential Issue

Mean For Preferential Issue A Preferential issue is an issue of stocks or of convertible securities through listed firms to a select number of person's under Section 81 of ...…

Definition for Share

Definition for Share The Certificates representing one unit of ownership in a mutual fund, corporation and limited partnership, the share has a certain declared face value, ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics